Shares of Valeant Pharmaceuticals International Inc. (NYSE:VRX) were down 3.3% during trading on Friday . The stock traded as low as $22.23 and last traded at $22.37, with a volume of 8,816,794 shares. The stock had previously closed at $23.13.

Several analysts recently commented on VRX shares. Rodman & Renshaw reaffirmed a “buy” rating on shares of Valeant Pharmaceuticals International in a research note on Sunday, April 3rd. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Valeant Pharmaceuticals International in a research note on Tuesday, April 5th. Canaccord Genuity reaffirmed a “hold” rating on shares of Valeant Pharmaceuticals International in a research note on Tuesday, April 5th. BMO Capital Markets reaffirmed a “market perform” rating and set a $66.00 price objective on shares of Valeant Pharmaceuticals International in a research note on Thursday, April 7th. Finally, BTIG Research reaffirmed a “neutral” rating on shares of Valeant Pharmaceuticals International in a research note on Thursday, April 7th. Seven research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $64.39.

The firm has a 50 day moving average price of $22.44 and a 200-day moving average price of $44.64. The company’s market cap is $7.65 billion.

Valeant Pharmaceuticals International (NYSE:VRX) last released its earnings results on Tuesday, June 7th. The specialty pharmaceutical company reported $1.27 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.37 by $0.10. During the same period in the prior year, the company earned $2.36 earnings per share. The firm had revenue of $2.37 billion for the quarter, compared to analysts’ expectations of $2.34 billion. The firm’s revenue for the quarter was up 9.3% on a year-over-year basis. Equities analysts expect that Valeant Pharmaceuticals International Inc. will post $6.56 EPS for the current year.

In related news, CEO Joseph C. Papa bought 202,000 shares of Valeant Pharmaceuticals International stock in a transaction dated Friday, June 10th. The stock was purchased at an average cost of $24.48 per share, with a total value of $4,944,960.00. Following the transaction, the chief executive officer now directly owns 2,442,199 shares of the company’s stock, valued at $59,785,031.52. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Other hedge funds and institutional investors recently added to or reduced their stakes in the company. Nicholas Co. Inc. WI increased its position in Valeant Pharmaceuticals International by 15.6% in the fourth quarter. Nicholas Co. Inc. WI now owns 1,586,925 shares of the specialty pharmaceutical company’s stock worth $161,310,000 after buying an additional 214,435 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Valeant Pharmaceuticals International by 3.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 79,777 shares of the specialty pharmaceutical company’s stock worth $8,110,000 after buying an additional 2,500 shares during the last quarter. BNP Paribas Arbitrage SA boosted its stake in shares of Valeant Pharmaceuticals International by 253.0% in the fourth quarter. BNP Paribas Arbitrage SA now owns 284,308 shares of the specialty pharmaceutical company’s stock worth $28,900,000 after buying an additional 203,760 shares during the last quarter. I.G. Investment Management LTD. boosted its stake in shares of Valeant Pharmaceuticals International by 31.0% in the fourth quarter. I.G. Investment Management LTD. now owns 1,328,610 shares of the specialty pharmaceutical company’s stock worth $135,033,000 after buying an additional 314,616 shares during the last quarter. Finally, Diamond Hill Capital Management Inc. boosted its stake in shares of Valeant Pharmaceuticals International by 77.8% in the fourth quarter. Diamond Hill Capital Management Inc. now owns 301,374 shares of the specialty pharmaceutical company’s stock worth $30,635,000 after buying an additional 131,832 shares during the last quarter.

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.